What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab.

What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab. J Drugs Dermatol. 2018 Aug 01;17(8):s29-s34 Authors: Hashim PW, Chen T, Lebwohl MG, Marangell LB, Kircik LH Abstract Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe plaque psoriasis. However, based on safety signals identified in clinical trials, brodalumab carries a boxed warning regarding possible risks of suicidal ideation and behavior (SIB). The validity of this link remains controversial, especially in the context of the psoriasis population as well as clinical trial data from other recently approved treatments. Herein, we critically examine the association between brodalumab and SIB. J Drugs Dermatol. 2018;17(8 Suppl):s29-34. PMID: 30124737 [PubMed - in process]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research